非维生素K拮抗剂口服抗凝药对非瓣膜病房颤患者左心房/左心耳血栓的消退效果
本研究前瞻性分析3 042例非瓣膜病房颤患者,经TEE检出左心房/左心耳血栓57例,最终19例接受达比加群酯或利伐沙班并复查TEE。结果显示NOAC可使部分血栓完全消退,高剂量可能更有效,随访期间无卒中、外周动脉栓塞和主要出血事件。
要点
- NOAC可使非瓣膜病房颤患者的左心房/左心耳血栓消退。
- 高剂量NOAC可能比低剂量血栓消退效果更好。
- 治疗及随访期间无卒中、外周动脉栓塞和主要出血事件。
核心结论
- NOAC是治疗左心房/左心耳血栓的有效选择。
- 在条件允许时,可能优先选择较高剂量的NOAC以提高血栓消退效果。
研究设计与样本
- 前瞻性连续筛查2016年3月至2018年1月因房颤行电复律或导管消融术前TEE检查的患者3 042例。
- TEE证实左心房/左心耳血栓57例,排除38例后最终入选19例接受达比加群酯或利伐沙班并复查TEE的非瓣膜病房颤患者。
主要发现
- 达比加群酯110 mg bid治疗4例,中位119(47,258)天,无患者血栓完全消退。
- 达比加群酯150 mg bid治疗11例,中位80(58,147)天,5例血栓完全消退。
- 利伐沙班15 mg qd治疗2例(分别110和95天),2例血栓完全消退;利伐沙班20 mg qd治疗2例(分别91和90天),1例血栓完全消退。
- 第二次复查TEE:达比加群酯110 mg bid未消退的3例改为150 mg bid后2例消退;达比加群酯150 mg bid未消退的4例中3例经调整后消退;利伐沙班20 mg qd未消退的1例改为15 mg bid后消退。
- 中位随访462(305,558)天,无临床血栓栓塞或主要出血事件。
临床怎么用
- 对非瓣膜病房颤合并左心房/左心耳血栓患者,可考虑使用NOAC治疗。
- 在患者条件允许时,可能优先选用较高剂量的NOAC以促进血栓消退。
局限性
- 样本量小(最终入选19例),各治疗组例数少。
- 为单中心前瞻性观察性研究,非随机对照设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the effect of non-vitamin K antagonist oral anticoagulants (NOAC) on left atrial or atrial appendage (LA/LAA) thrombi in patients with nonvalvular atrial fibrillation (NVAF). Method: Data from 3 042 patients with atrial fibrillation(AF), who underwent transesophageal echocardiography (TEE) examination before cardioversion or catheter ablation for the detection of LA/LAA thrombus in our department from March 2016 to January 2018 were prospectively analyzed. Among these patients, LA/LAA thrombus was detected by TEE in 57 patients. A total of 19 patients who received dabigatran or rivaroxaban for ≥3 weeks and underwent repeated TEE were included, 38 patients were excluded (7 patients with rheumatic heart disease, 1 patient treated with pericardial decortication, 1 patient treated with surgical repair of endocardial cushion defect, 1 patient with LA thrombus associated with the atrial septal occluder device, 14 patients received warfarin therapy, 14 patients did not receive repeated TEE). Results: First repeated TEE results showed that LA/LAA thrombus was not completely resolved in 4 out of 4 patients treated with dabigatran (110 mg bid) for a median time of 119 (47, 258) days, whereas LA/LAA thrombus was completely resolved in 5 out of 11 patients treated with dabigatran (150 mg bid) for a median time of 80 (58, 147) days. Thrombus was completely resolved in 2 out of 2 patients treated with rivaroxaban (15 mg qd) for 110 days and 95 days respectively, and in 1 out of 2 patients treated with rivaroxaban (20 mg qd) for 91 days. Second repeated TEE was performed in 8 patients. Thrombus was resolved completely in 2 out of 3 patients with undissolved thrombus treated by dabigatran (110 mg bid) after increasing the dabigatran dosage (150 mg bid). Thrombus was resolved in 3 (1 patient prolonged treatment with dabigatran 150 mg bid and 2 patients switched to rivaroxaban 20 mg qd) out of 4 patients with undissolved thrombus under the dabigatran 150 mg bid regimen, whereas the thrombus remained unresolved in 1 patient switched to rivaroxaban (15 mg qd). After receiving rivaroxaban 15 mg bid treatment, the thrombus was finally resolved in 1 patient with undissolved thrombus treated by rivaroxaban 20 mg qd. There was no clinical thromboembolism or major bleeding events during the median follow up time of 462 (305, 558) days. Conclusions: Our data show that NOAC is an effective therapeutic option for the treatment of LA/LAA thrombi. When eligible, a higher NOAC dosage may be preferred due to the higher efficacy on thrombus resolvement. 目的: 观察非维生素K拮抗剂口服抗凝药(NOAC)对非瓣膜病心房颤动(房颤)患者左心房/左心耳(LA/LAA)血栓消退的影响。 方法: 前瞻性连续筛查3 042例2016年3月1日至2018年1月1日在北京安贞医院因房颤行心脏电复律或导管消融术,术前行经食管超声心动图检查(TEE)的患者。TEE证实有LA/LAA血栓57例,除外38例(7例风湿性瓣膜病,1例心包剥脱术后,1例心内膜垫缺损矫治术后,1例房间隔封堵器血栓,14例接受华法林抗凝,14例未复查TEE),最终入选19例接受达比加群酯或利伐沙班治疗并复查TEE的非瓣膜病房颤患者,观察服用NOAC≥3周后血栓的消退效果。 结果: (1)抗凝后第1次复查TEE:服用达比加群酯110 mg、2次/d 4例,服用时间119(47,258)d,无患者血栓完全消退;服用达比加群酯150 mg、2次/d 11例,服用时间80(58,147)d,5例完全消退;服用利伐沙班15 mg、1次/d 2例,分别服用110和95 d,2例完全消退;服用利伐沙班20 mg、1次/d 2例患者,分别服用91和90 d,1例完全消退。(2)第2次复查TEE:服用达比加群酯110 mg、2次/d血栓未完全消退的3例患者,改为达比加群酯150 mg、2次/d,2例完全消退。服用达比加群酯150 mg、2次/d血栓未完全消退的4例患者,1例延长服用达比加群酯150 mg、2次/d,血栓完全消退;2例改服利伐沙班20 mg、1次/d,完全消退;1例改服利伐沙班15 mg、1次/d,仍有血栓。服用利伐沙班20 mg、1次/d血栓未完全消退的1例患者改为利伐沙班15 mg、2次/d,血栓完全消退。随访时间462(305,558)d,无卒中、外周动脉栓塞和主要出血事件发生。 结论: 提示NOAC可以使NVAF患者的LA/LAA血栓消退,高剂量的NOAC可能比低剂量的血栓消退效果更好。.
引用
- Cui J, Du X, Wu JH, et al. [Effect of non-vitamin K antagonist oral anticoagulants on left atrial or atrial appendage thrombi in patients with nonvalvular atrial fibrillation]. Zhonghua Xin Xue Guan Bing Za Zhi. 2018. PMID: 30139010. doi:10.3760/cma.j.issn.0253-3758.2018.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。